Intention to Grant a European patent on Sofdra applicator

• Botanix Pharmaceuticals receives Intention to Grant for European patent
• Patent covers proprietary applicator technology for Sofdra
• Expected to enhance value proposition for potential ex-US commercialization
• Patent protection expected until May 2039

Botanix Pharmaceuticals Limited, a commercial dermatology company, announced that the European Patent Office (EPO) has issued an Intention to Grant for European patent application EP 19799730.7, covering the proprietary applicator technology used with its sofpironium topical gel, branded as Sofdra in the US. This patent covers aspects of the applicator device designed to support controlled topical administration and patient use. The formal grant process and validation in selected European countries are expected to complete, providing protection into May 2039. The company believes this patent will strengthen its intellectual property estate and enhance the value proposition for potential ex-US commercialization pathways in Europe.